Bespoke research support for cancer immunotherapies (immuno oncology)
“We empower our clients with extensive domain expertise in the field of oncology therapy and offer customised research offerings across the oncology value chain”
Cancer immunotherapy (CIT) is a major pillar of cancer treatment, improving the prognosis of patients with a broad variety of haematological and solid malignancies. The two main drivers are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. CIT is a thriving field likely to become key in the fight against cancer.
Leading pharma companies including Roche, AstraZeneca, Bristol Myers Squibb, Pfizer and Merck are focusing on clinical trials with immune CPIs and CAR-T cell therapies across patient segments and tumour indications to stay competitive and meet rising demand for these therapies.
The increasing need for personalised therapies, the growing incidence of cancer, rising healthcare expenditure and recent approvals in PD-1 and PD-L1 inhibitors and CAR-T cell therapies will likely drive growth in the global cancer immunotherapeutics market.
Explore how our healthcare experts can provide support on the latest trends and emerging immunotherapies, current limitations, opportunities, developments and growth areas in this space
BENEFITS AND IMPACT
Domain expertise across the life sciences and healthcare ecosystem, with specialised expertise across therapeutic areas including oncology segments and rare diseases
Real-world expertise from solving challenges of 5 of the top 8 global pharmaceutical giants, meeting their strategic and business research needs
Actionable insights providing direct, meaningful action items for optimised decision making
Dedicated team that understands the specific needs of the life sciences sector, shares customised output and works towards building long-term client relationships
Flexible engagement models supporting changing requirements and dynamic market conditions to scale up or down, based on client requirement
Improved savings through operational cost savings, a dedicated team and automation
100% data confidentiality with industry-benchmarked SOC2 compliance
Cross-divisional support providing on-demand data analytics, financial services, deal tracking, commercial due diligence, M&A analysis and design and editorial support
Our offering
Strategy research and due diligence projects
Tap to flip
Our extensive research capabilities can help you efficiently manage increased demand
Life-cycle management strategy
Opportunity assessment and market attractiveness
Indication prioritisation
Product launch strategies
Licensing and acquisition
Market entry and due diligence
Pricing and reimbursement strategies
Technology or partner scouting
Support with pricing and drug launch strategies
Tap to flip
Our research team provides assistance with these strategies and with in-depth impact analysis
Global pricing strategy
Pre-launch planning and launch strategies
Drug pricing, reimbursement and market access analysis
Market sizing and forecasting
Market assessment and dynamics
Social media analytics
Market and competitive intelligence in the field of oncology therapy
Tap to flip
We manage the bulk of your research, enabling you to focus on core areas
Competitive intelligence and oncology pipeline analysis
Daily/weekly alerts tracking assets/competitors
KOL identification and primary research
Competitor profiling and benchmarking
Market assessment and sizing
Commercial and scientific conference coverage
Clinical trial site selection
Literature searches and newsletters
Support with regulatory policies in healthcare
Tap to flip
We have been keeping abreast of changes in regulation and help you create a master report along with daily/weekly alerts tracking changes
Regulatory approval in different countries
Regulatory requirements for clinical trials
Pricing and reimbursement policies
Patient access programmes
Macroeconomic policies of different countries
Thank you for sharing your details
Share this on
